Why Appetite Suppression Varies Between These Medications
Understanding Why Wegovy May Not Be Suppressing Appetite Effectively
When Wegovy isn't suppressing appetite as expected, the underlying mechanism helps explain why some patients benefit from considering Mounjaro as an alternative. Wegovy (semaglutide) works as a GLP-1 receptor agonist, mimicking a single fullness hormone to reduce appetite and promote satiety. However, Mounjaro (tirzepatide) takes a dual approach, targeting both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously.
This dual-receptor action may provide enhanced appetite suppression for patients who haven't achieved optimal results with Wegovy alone. Individual response to appetite suppression varies significantly, and factors including dose escalation timeline, eating patterns, and metabolic differences all influence how effectively either medication works. At EverydayMeds, our clinical team regularly supports patients exploring both options to find their most effective weight management approach.
Wegovy vs Mounjaro Pricing: Complete UK Cost Comparison
For patients considering switching from Wegovy when appetite suppression isn't optimal, understanding the complete pricing structure helps inform treatment decisions. Wegovy single pens range from £79.99 for the 0.25mg starter dose to £209.99 for the 2.4mg maintenance dose, with new customers using code FIRST40 at checkout. Mounjaro pricing follows a different structure, with doses from 2.5mg to 15mg available through the same clinical assessment process.
Both medications require careful dose escalation, meaning initial costs are lower during the titration phase before reaching maintenance doses. Our bundle options provide convenient multi-month supplies - for example, the Intro Trio (0.25mg, 0.5mg, 1mg) costs £299.99, covering your first 12 weeks of Wegovy treatment. Returning customers benefit from the DOSE25 discount code, and all orders include next-day cold-chain delivery once approved by our prescriber team.
Clinical Evidence: How Wegovy and Mounjaro Perform in Appetite Control Studies
Research into why Wegovy may not suppress appetite effectively in all patients highlights the importance of individualised treatment approaches. In clinical trials, patients taking Wegovy alongside diet and exercise achieved an average of ~clinically studied weight loss at 68 weeks in the STEP 1 trial (Wilding et al., NEJM, 2021). However, response rates varied considerably, with some patients experiencing minimal appetite suppression.
Mounjaro's dual-receptor mechanism has shown different appetite suppression patterns in clinical studies, though direct head-to-head comparisons use different trial designs. Both medications require prescription-only access and work most effectively when combined with dietary and lifestyle modifications, but the choice between them often depends on individual appetite response and tolerability profiles.
How Wegovy's GLP-1 Mechanism Affects Appetite Suppression
When Wegovy isn't suppressing appetite adequately, understanding its mechanism helps explain why switching to Mounjaro might provide different results. Wegovy works as a GLP-1 receptor agonist, binding to receptors in the brain's appetite centres and throughout the digestive system. This binding slows gastric emptying, meaning food stays in your stomach longer and promotes feelings of fullness after smaller meals. The medication also influences neural pathways that control food cravings and portion size preferences. However, individual variations in GLP-1 receptor sensitivity and distribution mean that appetite suppression effects can vary significantly between patients, which is why some people find better results with Mounjaro's additional GIP receptor targeting.
Simple Ordering Process for Both Wegovy and Mounjaro
Accessing either medication when Wegovy isn't suppressing appetite effectively involves the same streamlined process at EverydayMeds. Complete our 3-minute online clinical assessment, providing details about your current treatment experience and weight management goals. Your information goes to our qualified prescriber team for review, typically completed within 3 working days (or 24 hours with express service). Once approved, your medication ships via next-day cold-chain delivery, maintaining the required 2-8°C temperature throughout transit. Our GPhC-registered pharmacy (GPhC #9012878) ensures all medications meet UK safety standards, and you'll receive full injection guidance and ongoing support throughout your treatment journey.
Storage Differences: Wegovy vs Mounjaro Practical Considerations
Storage requirements differ between these medications, which may influence your choice if Wegovy hasn't been suppressing appetite effectively. Wegovy pens must be stored in the fridge at 2-8°C before first use, but offer excellent travel flexibility with 6 weeks of room temperature storage (below 30°C) once removed from refrigeration. Mounjaro has a shorter room temperature window at 21 days, making Wegovy more convenient for extended travel or varying schedules. Both use similar injection pen designs, though dose escalation schedules differ - Wegovy uses 5 dose strengths (0.25mg to 2.4mg) while Mounjaro offers 6 dose options (2.5mg to 15mg). Each injection is given once weekly, and the pre-filled FlexTouch pen design makes self-injection straightforward regardless of which medication you choose.
Individual Response Patterns: Why Appetite Suppression Varies
Understanding why Wegovy may not suppress appetite effectively for some patients involves recognising the complex individual factors that influence medication response. Genetic variations in GLP-1 receptor expression, baseline hormone levels, eating patterns, and metabolic health all contribute to how well appetite suppression occurs. Some patients find that Wegovy reduces cravings excellently but doesn't affect portion sizes, while others experience the opposite pattern.
Mounjaro's dual-receptor approach (GIP + GLP-1) may provide different appetite suppression characteristics, particularly for patients who haven't responded optimally to single-pathway medications. Factors like stress levels, sleep quality, meal timing, and concurrent medications can all influence how effectively either treatment suppresses appetite. This individual variation is why both medications remain available through EverydayMeds, allowing prescribers to match treatment approaches to patient-specific response patterns.
Making the Switch: From Wegovy to Mounjaro When Appetite Suppression Fails
When Wegovy isn't suppressing appetite effectively, transitioning to Mounjaro requires careful clinical consideration and prescriber guidance. Both are prescription-only medicines requiring individual assessment, and switching protocols depend on your current dose, treatment duration, and specific appetite suppression challenges. Your EverydayMeds prescriber can evaluate whether dose optimisation, timing adjustments, or medication switching offers the best approach for your situation. Our clinical team provides ongoing support throughout any transition, ensuring you maintain consistent weight management support while finding your most effective treatment option.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
